Flexible use of CCR5 in the absence of CXCR4 use explains the immune deficiency in HIV-1 infected children

AIDS

Volumn 24, Issue 16, 2010, Pages 2527-2533

  Cavarelli, Mariangela ^a   Karlsson, Ingrid ^b,d   Ripamonti, Chiara ^a   Plebani, Anna ^c   Fenyo, Eva Maria ^b   Scarlatti, Gabriella ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b LUND UNIVERSITY   (Sweden)

^c Clinica Pediatrica De Marchi   (Italy)

^d STATENS SERUM INSTITUT   (Denmark)

Author keywords

Children; Evolution; HIV 1; Immune deficiency; Phenotype

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; RANTES;

ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFANT; MOLECULAR EVOLUTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VIRUS INHIBITION; VIRUS ISOLATION; WILD TYPE;

DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE TOLERANCE; INFANT; INFANT, NEWBORN; MALE; PHENOTYPE; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 78549232578     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833d7d8c     Document Type: Article

References (30)

1. Auger I, Thomas P, De Gruttola V, Morse D, Moore D, Williams R, et al. Incubation periods for paediatric AIDS patients. Nature 1988;336:575-577.
2. Galli L, de Martino M, Tovo PA, Gabiano C, Zappa M, Gia- quinto C, et al. Onset of clinical signs in children with HIV-1 perinatal infection. Italian Register for HIV Infection in Children. AIDS 1995;9:455-461.
3. Mayaux MJ, Burgard M, Teglas JP, Cottalorda J, Krivine A, Simon F, et al. Neonatal characteristics in rapidly progressive perina- tally acquired HIV-1 disease. The French Pediatric HIV Infection Study Group. JAMA 1996;275:606-610.
4. Pizzo PA, Wilfert CM. Markers and determinants of disease progression in children with HIV infection. The Pediatric AIDS Siena Workshop II. J Acquir Immune Defic Syndr Hum Retroviral 1995;8:30-44.
5. Balotta C, Colombo MC, Colucci G, Vigano A, Riva C, Papagno L, et al. Plasma viremia and virus phenotype are correlates of disease progression in vertically human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 1997;16:205-211 .
6. Balotta C, Vigano A, Riva C, Colombo MC, Salvaggio A, de Pasquale MP, et al. HIV type 1 phenotype correlates with the stage of infection in vertically infected children. AIDS Res Hum Retroviruses 1996;12:1247-1253.
7. Kopka J, Batalla M, Mangano A, Mecikovsky D, Bologna R, Sen L. Relevance of viral phenotype in the early AIDS outcome of pediatric HIV-1 primary infection. Pediatr Res 2002;52:475-480.
8. Resino S, Gurbindo D, Cano JM, Sanchez-Ramon S, Muoz-Fernandez MA. Predictive markers of clinical outcome in vertically HIV-1-infected infants. A prospective longitudinal study. Pediatr Res 2000;47:509-515.
9. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997;3:1259-1265.
10. Strunnikova N, Ray SC, Livingston RA, Rubalcaba E, Viscidi RP. Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression. J Virol 1995;69:7548-7558.
11. Casper C, Naver L, Clevestig P, Belfrage E, Leitner T, Albert J, et al. Coreceptor change appears after immune deficiency is established in children infected with different HIV-1 subtypes. AIDS Res Hum Retroviruses 2002;18:343-352.
12. Cavarelli M, Karlsson I, Zanchetta M, Antonsson L, Plebani A, Giaquinto C, etal. HIV-1 with multiple CCR5/CXCR4 chimeric receptor use is predictive of immunological failure in infected children. PLoS ONE 2008; 3:e3292.
13. Karlsson I, Antonsson L, Shi Y, Oberg M, Karlsson A, Albert J, et al. Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol 2004;78:11807-11815.
14. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, et al. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 1999;96:11986-11991.
15. Meddows-Taylor S, Donninger SL, Paximadis M, Schramm DB, Anthony FS, Gray GE, et al. Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal human immunodeficiency virus 1 transmission. J Gen Virol 2006; 87:2055-2065.
16. Paxton WA, Neumann AU, Kang S, Deutch L, Brown RC, Koup RA, Wolinsky SM. RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression. J Infect Dis 2001;183:1678-1681.
17. Este JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, Henson G, et al. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol 1999; 73:5577-5585.
18. Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, et al. Highly potent RANTES analogues either prevent CCR5- using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999; 73:3544-3550.
19. Moncunill G, Armand-Ugon M, Pauls E, Clotet B, EsteJA. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS 2008; 22:23-31.
20. Koning FA, Kwa D, Boeser-Nunnink B, Dekker J, Vingerhoed J, Hiemstra H, Schuitemaker H. Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and secreted) neutralization of CC chemokine receptor 5-using, nonsyncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J Infect Dis 2003;188:864-872.
21. Repits J, Oberg M, Esbjornsson J, Medstrand P, Karlsson A, Albert J, et al. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol 2005;86:2859-2869.
22. Ripamonti C, Leitner T, Lauren A, Karlsson I, Pastore A, Cavarelli M, et al. Biological and genetic evolution of HIV type 1 in two siblings with different patterns of disease progression. AIDS Res Hum Retroviruses 2007;23:1531-1540.
23. Scarlatti G, Lombardi V, Plebani A, Principi N, Vegni C, Ferraris G, et al. Polymerase chain reaction, virus isolation and antigen assay in HIV-1-antibody-positive mothers and their children. AIDS 1991;5:1173-1178.
24. Romiti ML, Colognesi C, Cancrini C, Mas A, Berrino M, Salva- tori F, et al. Prognostic value of a CCR5 defective allele in pediatric HIV-1 infection. Mol Med 2000; 6:28-36.
25. Centers for Disease Control. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morbid Mortal Wkly Rep 1994; 43:1-10.
26. Karlsson I, Antonsson L, Shi Y, Karlsson A, Albert J, Leitner T, et al. HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use. AIDS 2003; 17:2561-2569.
27. Jansson M, Popovic M, Karlsson A, Cocchi F, Rossi P, Albert J, Wigzell H. Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci U S A 1996; 93:15382-15387.
28. Ullum H, Cozzi Lepri A, Victor J, Aladdin H, Phillips AN, Gerstoft J, et al. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1beta are associated with a decreased risk of HIV disease progression. J Infect Dis 1998;177:331-336.
29. Wu Yuntao, Yoder Alyson. Chemokine coreceptor signaling in HIV-1 infection and pathogenesis. PlosPathogens 2009;12:e1000520.
30. Gray L, Sterjovski J, Churchill M, Ellery P, Nasr N, Lewin SR, et al. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology 2005; 337:384-398.